Previous Close | 62.24 |
Open | 62.42 |
Bid | 0.00 x 900 |
Ask | 0.00 x 800 |
Day's Range | 61.80 - 63.21 |
52 Week Range | 57.19 - 74.12 |
Volume | |
Avg. Volume | 9,910,063 |
Market Cap | 79.247B |
Beta (5Y Monthly) | 0.42 |
PE Ratio (TTM) | 17.65 |
EPS (TTM) | 3.58 |
Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
Forward Dividend & Yield | 2.92 (4.62%) |
Ex-Dividend Date | Jun 14, 2022 |
1y Target Est | 69.35 |
Subscribe to Yahoo Finance Plus to view Fair Value for GILD
FOSTER CITY, Calif. & SANTA MONICA, Calif., May 17, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that more than 20 abstracts, including two oral presentations and four poster discussions, will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. These data highlight promising targets across diverse tumor types and blood cancers, including hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER
The FDA has lifted the clinical hold placed on Gilead Sciences Inc's (NASDAQ: GILD) Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis. The agency has removed the clinical hold after reviewing Gilead's comprehensive plan and corresponding data on the storage and compatibility of lenacapavir injection with an alternative vial made from aluminosilicate glass. Related: FDA Slaps Clinical Hold On Gilead's Injectable Lenacapavir
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.